Canada - English - Health Canada

huntington laboratories canada ltd. - benzalkonium chloride; didecyl dimethyl ammonium chloride - liquid - 3.07%; 4.61% - benzalkonium chloride 3.07%; didecyl dimethyl ammonium chloride 4.61% - disinfectants (for agents used on object)

Canada - English - Health Canada

huntington laboratories canada ltd. - didecyl dimethyl ammonium chloride; benzalkonium chloride - liquid - 7.5%; 5% - didecyl dimethyl ammonium chloride 7.5%; benzalkonium chloride 5% - disinfectants (for agents used on object)

Canada - English - Health Canada

huntington laboratories canada ltd. - benzalkonium chloride; alkyl dimethyl ethylbenzyl ammonium chloride - aerosol - .11%; .11% - benzalkonium chloride .11%; alkyl dimethyl ethylbenzyl ammonium chloride .11% - disinfectants (for agents used on object)

Canada - English - Health Canada

huntington laboratories canada ltd. - benzalkonium chloride; alkyl dimethyl ethylbenzyl ammonium chloride - liquid - .09%; .09% - benzalkonium chloride .09%; alkyl dimethyl ethylbenzyl ammonium chloride .09% - disinfectants (for agents used on object)

Canada - English - Health Canada

huntington laboratories canada ltd. - polyethoxy polypropoxy polyethoxy ethanol - iodine complex; nonyl phenoxypoly ethoxy ethanol-iodine - liquid - 11.3%; 10.8% - polyethoxy polypropoxy polyethoxy ethanol - iodine complex 11.3%; nonyl phenoxypoly ethoxy ethanol-iodine 10.8% - disinfectants (for agents used on object)

Canada - English - Health Canada

huntington laboratories canada ltd. - alcohol anhydrous - liquid - 70% - alcohol anhydrous 70% - miscellaneous local anti-infectives

Canada - English - Health Canada

huntington laboratories canada ltd. - chlorhexidine gluconate; isopropyl alcohol - liquid - 2%; 4% - chlorhexidine gluconate 2%; isopropyl alcohol 4% - miscellaneous local anti-infectives

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aop orphan ltd - tetrabenazine - oral tablet - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aop orphan ltd - tetrabenazine - oral tablet - 25mg

United States - English - NLM (National Library of Medicine)

dr. reddys laboratories inc - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington’s disease. tetrabenazine tablets are contraindicated in patients: • who are actively suicidal, or in patients with untreated or inadequately treated depression [see warnings and precautions ( 5.1) ]. • with hepatic impairment [see use in specific populations (8.6 ), clinical pharmacology ( 12.3) ]. • taking monoamine oxidase inhibitors (maois). tetrabenazine should not be used in combination with an maoi, or within a minimum of 14 days of discontinuing therapy with an maoi [see drug interactions (7.3)]. • taking reserpine. at least 20 days should elapse after stopping reserpine before starting tetrabenazine[see drug interactions ( 7.2 )]. • taking deutetrabenazine or valbenazine [see drug interactions (7.7)]. risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in